{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:31:51Z","timestamp":1786516311207,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020205","name":"Health Commission of Jiangxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"\n Introduction<\/jats:title>\n Acute lymphoblastic leukemia (ALL) is the most common pediatric hematologic malignancy, with the majority of cases being of B-cell origin. While many patients respond favorably to therapy, a subset experiences early relapse or poor outcomes, underscoring the critical need for reliable prognostic biomarkers. This study investigated the significance of CD123 expression in diagnosing the disease, evaluating therapeutic efficacy, and predicting prognosis in pediatric B-cell ALL (B-ALL).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This retrospective study included 305 pediatric patients with B-ALL admitted to our hematology department from January 2016 to December 2021. All patients were treated following the CCCG-ALL-2015 protocol. Based on flow cytometric evaluation, patients with \u226520% or &lt;20% CD123-expressing blasts were stratified into CD123-positive (CD123\n +<\/jats:sup>\n ) and CD123-negative (CD123\n \u2212<\/jats:sup>\n ) groups, respectively.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n CD123 was expressed on the leukemic blasts of 60.3% of patients, exhibiting a strong positive correlation with CD34 expression (\n P<\/jats:italic>\n \u2009&lt;\u20090.001). CD123 positivity was substantially associated with specific genetic abnormalities. Specifically, the frequencies of the\n ETV6::RUNX1<\/jats:italic>\n and\n TCF3::PBX1<\/jats:italic>\n fusion genes were significantly lower in the CD123\n +<\/jats:sup>\n group than in the CD123\n \u2212<\/jats:sup>\n group. The 5-year event-free survival (EFS) rate was significantly higher in the CD123\n +<\/jats:sup>\n group than in the CD123\n \u2212<\/jats:sup>\n group (\n P<\/jats:italic>\n \u2009=\u20090.027). This favorable prognostic impact was particularly pronounced in patients exhibiting minimal residual disease (MRD) positivity on day 19 (\n P<\/jats:italic>\n \u2009=\u20090.006). Furthermore, combining CD123 status with day 19 MRD enabled more accurate identification of patients with a poor prognosis.\n <\/jats:p>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n CD123 positivity on leukemic blasts correlates with distinct genetic profiles and favorable clinical outcomes in pediatric B-ALL. Ultimately, integrating CD123 status with early treatment response facilitates accurate risk stratification and guides personalized therapeutic strategies.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fped.2026.1887012","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:00:05Z","timestamp":1786514405000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic implications of CD123 in pediatric B-cell acute lymphoblastic leukemia: a single-center retrospective analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Zheng","family":"Li","sequence":"first","affiliation":[{"name":"Department of Hematology, Jiangxi Provincial Children\u2019s Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinfa","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangxi Provincial Children\u2019s Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangxi Provincial Children\u2019s Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangxi Provincial Children\u2019s Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1182\/blood.2023023336","article-title":"Germ line genetic NBN variation and predisposition to B-cell acute lymphoblastic leukemia in children","volume":"143","author":"Carolin","year":"2024","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1182\/blood.2024026381","article-title":"Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL","volume":"145","author":"Zhang","year":"2025","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/bjh.12442","article-title":"Predicting relapse risk in childhood acute lymphoblastic leukaemia","volume":"162","author":"Teachey","year":"2013","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/ajh.25124","article-title":"Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: the first nation-wide prospective multicenter study in China","volume":"93","author":"Cui","year":"2018","journal-title":"Am J Hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.22.01760","article-title":"Childhood acute lymphoblastic leukemia: results of the randomized acute lymphoblastic leukemia intercontinental- Berlin-Frankfurt-M\u00fcnster 2009 trial","volume":"41","author":"Campbell","year":"2023","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3109\/08977194.2011.649919","article-title":"The GM-CSF receptor family: mechanism of activation and implications for disease","volume":"30","author":"Hercus","year":"2012","journal-title":"Growth Factors"},{"key":"B8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000480448","article-title":"CD34+CD38-CD123+ cells are present in virtually all acute myeloid leukaemia blasts: a promising single unique phenotype for minimal residual disease detection","volume":"138","author":"Al-Mawali","year":"2017","journal-title":"Acta Haematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomark Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3760\/cn121090-20231123-00272","article-title":"Preparation of a dual-specific antibody targeting human CD123 and exploration of its anti-acute myeloid leukemia effects","volume":"45","author":"Zhou","year":"2024","journal-title":"Chin J Hematol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1200\/JCO.21.01595","article-title":"CD123 expression is associated with high-risk disease characteristics in childhood acute myeloid leukemia: a report from the children\u2019s oncology group","volume":"40","author":"Lamble","year":"2021","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s12185-019-02616-y","article-title":"Impact of CD123 expression, analyzed by immunohistochemistry on clinical outcomes in patients with acute myeloid leukemia","volume":"109","author":"Arai","year":"2019","journal-title":"Int J Hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1158\/1078-0432.CCR-16-1904","article-title":"Antileukemia efficacy and mechanisms of action of SL-101, a novel anti-CD123 antibody conjugate, in acute myeloid leukemia","volume":"23","author":"Han","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1038\/mt.2016.116","article-title":"CD123-engager T cells as a novel immunotherapeutic for acute myeloid leukemia","volume":"24","author":"Bonifant","year":"2016","journal-title":"Mol Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/cac2.12474","article-title":"Novel CD123\u00d7CD33 bicistronic chimeric antigen receptor (CAR)-T therapy has potential to reduce escape from single-target CAR-T with no more hematotoxicity","volume":"43","author":"Wang","year":"2023","journal-title":"Cancer Commun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/archdischild-2018-316181","article-title":"Treatment abandonment in childhood acute lymphoblastic leukaemia in China: a retrospective cohort study of the Chinese children\u2019s cancer group","volume":"104","author":"Cai","year":"2019","journal-title":"Arch Dis Child"},{"key":"B18","doi-asserted-by":"publisher","first-page":"614420","DOI":"10.3389\/fonc.2021.614420","article-title":"High expression of interleukin-3 receptor alpha chain (CD123) predicts favorable outcome in pediatric B-cell acute lymphoblastic leukemia lacking prognosis-defining genomic aberrations","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3324\/haematol.2018.205252","article-title":"CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia","volume":"104","author":"Angelova","year":"2019","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/cyto.b.22086","article-title":"Immunophenotypic characteristics of ZNF384 rearrangement compared with BCR-ABL1, KMT2A rearrangement, and other adult B-cell precursor acute lymphoblastic leukemia","volume":"102","author":"Wang","year":"2022","journal-title":"Cytometry B Clin Cytom"},{"key":"B21","doi-asserted-by":"publisher","first-page":"a028514","DOI":"10.1101\/cshperspect.a028514","article-title":"Role of the \u03b2common (\u03b2c) family of cytokines in health and disease","volume":"10","author":"Hercus","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"ltad027","DOI":"10.1093\/immadv\/ltad027","article-title":"Janus kinase inhibitors ameliorate clinical symptoms in patients with STAT3 gain-of-function","volume":"3","author":"Kaneko","year":"2023","journal-title":"Immunother Adv"},{"key":"B23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2024.11.011","article-title":"Cytokines in cancer","volume":"43","author":"Kureshi","year":"2025","journal-title":"Cancer Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.immuni.2019.03.022","article-title":"GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation","volume":"50","author":"Dougan","year":"2019","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.1182\/blood-2010-09-309179","article-title":"Overexpression of IL-3Ralpha on CD34+CD38- stem cells defines leukemia-initiating cells in Fanconi anemia AML","volume":"117","author":"Du","year":"2011","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","article-title":"Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis","volume":"100","author":"Testa","year":"2002","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.4049\/jimmunol.165.5.2382","article-title":"IL-3 increases production of B lymphoid progenitors from human CD34+CD38- cells","volume":"165","author":"Crooks","year":"2000","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1038\/s41467-018-05984-x","article-title":"Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes","volume":"9","author":"Stevens","year":"2018","journal-title":"Nat Commun"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1887012\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:00:06Z","timestamp":1786514406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1887012\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":29,"alternative-id":["10.3389\/fped.2026.1887012"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1887012","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1887012"}}